ICER in empirical treatment scenario. Incremental cost per additional disability-adjusted life years averted by using the BPaLM regimen instead of the BPaL regimen in an empirical treatment setting without fluoroquinolone drug susceptibility testing. Interquartile ranges reflect the uncertainty around the ICER estimates based on probabilistic sensitivity analyses. DALYs disability-adjusted life years; ICER Incremental cost-effectiveness ratio.

ICER in empirical treatment scenario. Incremental cost per additional disability-adjusted life years averted by using the BPaLM regimen instead of the BPaL regimen in an empirical treatment setting without fluoroquinolone drug susceptibility testing. Interquartile ranges reflect the uncertainty around the ICER estimates based on probabilistic sensitivity analyses. DALYs disability-adjusted life years; ICER Incremental cost-effectiveness ratio.

经验治疗场景下的增量成本效果比（Incremental cost-effectiveness ratio, ICER）。即在未开展氟喹诺酮类药物药敏试验的经验治疗环境中，以BPaLM方案替代BPaL方案时，每额外挽回1个伤残调整寿命年（disability-adjusted life years, DALYs）所需的增量成本。四分位间距反映了基于概率敏感性分析得到的ICER估计值的不确定性。注：DALYs即伤残调整寿命年（disability-adjusted life years）；ICER即增量成本效果比（Incremental cost-effectiveness ratio）。